Compare AT&T Inc. (T) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs 10X Genomics Inc — how do they compare? AT&T Inc. trades at $22.64 (market cap $170.42B), while 10X Genomics Inc trades at $81.35 (market cap $10.07B). The key difference: AT&T Inc. is far larger — about 16.9× 10X Genomics Inc's market cap, and AT&T Inc. pays a 4.46% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold AT&T Inc. for 118 Days and 10X Genomics Inc for 92 Days on average.
| T | TXG | |
|---|---|---|
Market Cap | $170.42B | $10.07B |
Volume | 50,780,036 | 5,657,286 |
Sector | Media | Health |
52-Week High | $29.10 | $97.74 |
52-Week Low | $20.49 | $11.48 |
Typical Hold Time | 118 Days | 92 Days |
Enterprise Value | $315.74B | $9.59B |
Dividend Yield | 4.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $24.48, up 0.2% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.2, 16.9% net margin, and consistent dividend payments. Revenue grew to $125.7B in 2025, while debt reduction and fiber expansion with Corning highlight strategic initiatives. Analyst consensus is mixed with 44% buy ratings and a $27.61 price target.
The outlook balances value appeal against competitive pressures. The low valuation and 4% yield attract income investors, but legacy revenue declines and high debt pose risks. Fiber investments and wireless growth offer upside, yet execution and market saturation remain challenges. The stock presents a dividend-income opportunity with moderate growth potential in a competitive telecom landscape.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
